Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Non-Current Deffered Revenue (2019 - 2025)

Outset Medical (OM) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $406000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 51.9% to $406000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $406000.0, a 51.9% decrease, with the full-year FY2025 number at $406000.0, down 51.9% from a year prior.
  • Non-Current Deffered Revenue was $406000.0 for Q4 2025 at Outset Medical, down from $676000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $844000.0 in Q4 2024 to a low of $77000.0 in Q3 2024.
  • A 5-year average of $313950.0 and a median of $190000.0 in 2022 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 80.74% in 2021, then surged 777.92% in 2025.
  • Outset Medical's Non-Current Deffered Revenue stood at $312000.0 in 2021, then crashed by 51.6% to $151000.0 in 2022, then tumbled by 33.11% to $101000.0 in 2023, then soared by 735.64% to $844000.0 in 2024, then plummeted by 51.9% to $406000.0 in 2025.
  • Per Business Quant, the three most recent readings for OM's Non-Current Deffered Revenue are $406000.0 (Q4 2025), $676000.0 (Q3 2025), and $587000.0 (Q2 2025).